Johnson & Johnson (JNJ) reported Q4 FY 2021 earnings of $2.13 per share (versus $1.86 per share in Q4 FY 2020), marginally beating analysts’ consensus estimate of $2.12 per share.
The company’s quarterly revenues amounted to $24.804 bln (+10.4% y/y), missing analysts’ consensus estimate of $25.290 bln.
The company also issued upside guidance for FY 2022, seeing EPS of $10.40-$10.60 versus analysts’ consensus estimate of $10.32 and revenues of $98.9-$100.4 bln versus analysts’ consensus estimate of $97.7 bln.
JNJ fell to $158.70 (-2.62%) in pre-market trading.
